

# A Scoping Review of the Transcriptomic Perspective of Sepsis, a Move Towards Improved Precision Medicine?

**Asrar Rashid**<sup>\*1,2</sup>, Kwame Wiredu<sup>3</sup>, Hoda Alkhazaimi<sup>4</sup>, Benjamin Hanisch<sup>5</sup>, Praveen Khilnani<sup>6</sup>, Princess Anne C. Derigay<sup>7</sup>, Christos Koutentis<sup>8</sup>, Berit S Brusletto<sup>9</sup>, Mohammed Toufiq<sup>10</sup>, Zain Hussain<sup>11</sup>, Harish Vyas<sup>12</sup>, Govind Benakatti<sup>13</sup>, Zainab Malik<sup>14,15</sup>, Maik Schumacher<sup>16</sup>, Rashid Nadeem<sup>17</sup>, Rayaz Malik<sup>18,19</sup>, Shriprasad Deshpande<sup>5</sup>, Nuha Kidwai<sup>20</sup>, Raziya Kadwa<sup>2</sup>, Amrita Sarpal<sup>21</sup>, M.Guftar Shaikh<sup>22</sup>, Javed Sharief<sup>2</sup>, Syed Ahmed Zaki<sup>23</sup>, Rajesh Phatak<sup>24</sup>, Mishtal Tariq<sup>2</sup>, Akash Deep<sup>25</sup>, Mouhamad Al Zouhbi<sup>2</sup>, Husam Saleh<sup>2</sup>, Ahmed Al-Dubai<sup>1</sup>, Amir Hussain<sup>1</sup>

\*Corresponding Author Dr. Asrar Rashid, Doctoral Fellow Napier University

1. School of Computing, Edinburgh Napier University, UK
2. NMC Royal Hospital, Abu Dhabi, UAE
3. Harvard Medical School, MA, USA
4. New York University Abu Dhabi, UAE
5. Children's National Hospital, Washington DC
6. Rainbow Children's Hospital, Delhi, India.
7. University of San Carlos, Philippines
8. Department of Anesthesiology, SUNY Downstate Medical Center
9. The Blood Cell Research Group, Department of Medical Biochemistry, Oslo University Hospital; Ullevål, Norway
10. The Jackson Laboratory, USA
11. Edinburgh Medical School, University of Edinburgh, Edinburgh, UK.
12. Harish Vyas, Nottingham University, UK
13. Zulekha Hospital, Dubai, UAE
14. College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE
15. Mediclinic City Hospital, UAE
16. Sheikh Khalifa Medical City, UAE
17. Dubai Hospital, Dubai, UAE
18. Institute of Cardiovascular Science, University of Manchester. Manchester, UK.
19. Weill Cornell Medicine-Qatar, Doha, Qatar
20. North London Collegiate, Dubai, UAE
21. Sidra Medicine, Doha, Qatar
22. Department of Endocrinology, Royal Hospital for Children, Glasgow, UK
23. All India Institute of Medical Sciences Hyderabad
24. Pediatric Intensive Care, Burjeel Hospital, Najda, Abu Dhabi
25. Paediatric Intensive Care Unit, King's College Hospital, London, United Kingdom

Using WGCNA, Chao et al identified key genes (MMP9 and C3AR1), both associated with sepsis prognosis and the pattern of cellular infiltration (1). Xiaojie et al developed a 10-core gene panel for the diagnosis of sepsis derived from a WGCNA workflow (2). Through a secondary analysis, Yiping Li et al (3) related four modules to Wong et al pediatric sepsis dataset (4), identifying key hub genes. From this work, Yiping then validated the hub genes by qPCR, evidencing the transcription of the hub genes in a prospective case-control validation study. Thereby suggesting that hub genes have the potential use as biomarkers in pediatric sepsis.

Zhang et al also analyzed an adult ICU dataset (5) using WGCNA methodology to highlight significant gene modules in sepsis (6). Also, Li et al. used WGCNA to demonstrate inflammation-related genes and to identify transcriptomic markers (7). Furthermore, in this study, WGCNA was integrated with the support vector machine (SVM) algorithm. This led to the identification of a four-gene signature modular model allowing sepsis diagnosis. Yao et al. also used WGCNA to identify a four-gene signature with a good predictive value for the diagnosis of sepsis(8).

## **Abstract**

### **Background**

Sepsis is a syndromic response to infection that carries a significant global health burden, with 11 million deaths reported globally in 2017. Many biomarkers have been developed over the years for early identification and prognosis in patients with sepsis. However, they lack the sensitivity and specificity for routine use in clinical practice. A significant challenge in developing a sepsis biomarker has been the lack of a robust pathobiological framework: a factor with a weak immunological basis to assess therapeutic efficacy. The transcript can aid in extrapolating immunological changes to the clinical arena. Given that transcriptomic processing forms a part of a systems biology analysis, we undertook to address the question: *What is known about the relationship of the transcript to clinical sepsis?*

### **Objective**

Consequently, this review article envisages a systems-based approach to better understand sepsis using mRNA gene expression information. This was achieved through an examination of peer-reviewed literature identifying the relationship of the transcript to clinical sepsis.

### **Methods**

Information sources included peer-reviewed PubMed-indexed journals using the PubMed database. To be eligible, articles specific to sepsis were selected,

being published between the years 2012 to 2022 inclusive. A content analysis of findings was conducted.

## **Results**

The search strategy elicited 14,048 studies. Keywords and or mesh terms were applied as single terms or Boolean string search combinations, generating 36 studies. Literature was analyzed concerning the specific use of the transcript and its application to sepsis. Five main descriptive Sepsis categories were identified: (1) Definition; (2) Classification; (3) Severity, (4) Molecular Biomarkers, and (5) Benchmarking.

## **Conclusions**

Evidence of the connection of the transcript to clinical sepsis was identified. This provided a systems perspective, interfacing transcriptomic data to parameters important in the clinical arena. The use of transcriptomic data in advancing patient sepsis care, thereby aiming to improve precision, requires further investigation.

## **2.1 Introduction, Current Challenges in Sepsis Definition, and the value of the Transcript in a Systems Biology Approach**

Sepsis remains a significant contributor to in-hospital deaths globally, representing a significant and underestimated public health burden, especially in children (9). Despite decades of research, tens of thousands of publications, and hundreds of millions of dollars spent, we have yet to identify and adopt into clinical practice a groundbreaking diagnostic approach, therapeutic agent, or prognostic model for sepsis(10). Consensus international protocols in adult and pediatric sepsis have aimed to counter this situation(11, 12). They are driving a global response to improve sepsis management. However, despite the best intentions, a modern-day understanding of sepsis pathogenesis remains incomplete. Contributing to the fact that a precise all-encompassing definition of sepsis remains elusive for neonates, children, and adults(13-15). Additionally, expert panels have acknowledged weaknesses in internationally compiled sepsis protocols (16). Further, an effective, helpful immunomodulator remains elusive, apart from early antibiotic treatment, fluids, and drugs for circulatory support. For example, candidate agents, such as Activated Protein-C and Vitamin C, were introduced without the desired efficacy (17, 18). This underlines the shortcomings of current scientific knowledge and approach to sepsis(19, 20).

Hence there is a drawback caused by the knowledge gap between the current immunological understanding of sepsis and the translation to the bedside. Exploring the immunological response to sepsis is key to driving improved

clinical outcomes. An important area of focus is the transition from infection to sepsis and then to septic shock. Such disease progression, through the continuum of bacteremia to infection to sepsis, is linked to a ‘sepsis trajectory’ and is poorly understood(21). Underlying factors determining disease progression include the combination of innate and adaptive immune mechanisms, the severity of infection, host age, adequacy of treatment provided, and genetic susceptibility. Further, host-pathogen interactions are instrumental in triggering an infective state, activating the host’s immune response, and eventually resulting in sepsis. The major problem underlying clinical interpretation and the application of scientific research is that a conclusive relationship between sepsis pathophysiology and immunological changes remains elusive.

One of the challenges when developing any framework to understand sepsis is the considerable variability in the sepsis host-pathogen response(22). Complexity is also compounded by the fact that genetic determinants for sepsis are only partially understood. Added to this, variations in clinical care quality also affect the natural history of sepsis. For example, Lorton et al. (2022) demonstrated 10.4 % mortality and 9.6% morbidity in a 259-child cohort, of which 34.4% received sub-optimal care(23). The aforementioned factors mean that sepsis is a heterogeneous process. Translating basic science research to the clinical arena, therefore, remains highly challenging.

Attempting to bridge this gap provides a suitable rationale for this scoping review. On this basis, the objective is to understand how a systems

based-approach can associate immunological perspectives translatable to clinical perspectives pertinent to sepsis. Omic strategies have aided the translation and application of genomic knowledge to the bedside. Further, transcriptomic analysis has been utilized as a part of a systems-based approach, helpful in understanding complex biological processes (24). An example is the transcriptome application for precision medicine approaches in sepsis (25). Given the increased application of transcriptomics to various clinical conditions, this paper aims to use the genomic construct to bind scientific interpretation to clinical sepsis translation. Thereby, this paper seeks to expand our knowledge of the application of the transcript to the study of sepsis. Specifically, this scoping review aims to examine peer review literature identifying the utilization of transcriptomic information applied to clinical sepsis over the past decade (2012-2021), including the potential for enhanced sepsis biomarking (26).





## **2.1 Introduction, Current Challenges in Sepsis Definition, and the value of the Transcript in a Systems Biology Approach**

Sepsis remains a significant contributor to in-hospital deaths globally, representing a significant and underestimated public health burden, especially in children (9). Despite decades of research, tens of thousands of publications, and hundreds of millions of dollars spent, we have yet to identify and adopt into clinical practice a groundbreaking diagnostic approach, therapeutic agent, or prognostic model for sepsis(10). Consensus international protocols in adult and pediatric sepsis have aimed to counter this situation(11, 12). They are driving a global response to improve sepsis management. However, despite the best intentions, a modern-day understanding of sepsis pathogenesis remains incomplete. Contributing to the fact that a precise all-encompassing definition of sepsis remains elusive for neonates, children, and adults(13-15). Additionally, expert panels have acknowledged weaknesses in internationally compiled sepsis protocols (16). Further, the lack of a helpful immunomodulator remains elusive, apart from early antibiotic treatment, fluids, and drugs for circulatory support. For example, candidate agents, such as Activated Protein-C and Vitamin C, were introduced without the desired efficacy (17, 18). This underlines the shortcomings of current scientific knowledge and approach to sepsis(19, 20).

Understanding the immunological response to sepsis is key to driving improved clinical outcomes. An important area of focus is the transition from infection to sepsis. Disease progression, through the continuum of bacteremia

to infection to sepsis, we term the ‘sepsis trajectory.’ Underlying factors determining disease progression include the combination of innate and adaptive immune mechanisms, the severity of infection, host age, adequacy of treatment provided, and genetic susceptibility. Further, host-pathogen interactions are instrumental in triggering an infective state, activating the host immune response, and eventually leading to sepsis. How infection results in septic shock and the dynamic changes involved are not fully understood(21). Problematic is the fact that the relationship binding sepsis pathophysiology to immune changes remains elusive.

Further, there is considerable variability in the sepsis host-pathogen response(22). The contribution of genetic predisposition is also partially understood. Moreover, variations in clinical care quality also affect the natural history of sepsis. For example, Lorton et al. (2022) demonstrated 10.4 % mortality and 9.6% morbidity in a 259-child cohort, of which 34.4% received sub-optimal care(23). Due to such heterogeneity, translating basic science research to the clinical arena remains highly challenging. Clinical consequences of sepsis, unabated, resulting in severe organ dysfunction. This eventually results in physiological instability and septic shock. Single-organ dysfunction in sepsis is rare, with the subsequent failure of each organ being associated with an increased risk of a poor outcome(27).

An inflammatory cascade termed Systemic Inflammatory Response Syndrome (SIRS) was initially thought to be followed by anti-inflammation (28).

Transcriptomic analysis suggests this interpretation to be simplistic. For example, Bauer et al. (2016) showed that anti-inflammatory and immunosuppressive transcript biomarkers improve infection diagnosis and outcome prognostication(29). Possibly anti-inflammatory responses and defective adaptive immune reactions occur in unison. Thus suggesting an overlap of anti-inflammation with compromised adaptive immune response. A vital leap occurred when Sepsis was redefined in the 2016 third international consensus definitions for sepsis and septic shock, known as ‘Sepsis-3’(30). Here a dysregulated host immune response was a critical differentiator between infection and sepsis, with sepsis resulting in organ dysfunction. Other aspects important in relation to the development of sepsis include sepsis genetic susceptibility from mendelian single-gene mutations as directly causing a susceptible host to more subtle multi-factorial determinants involving genetic variants and gene polymorphisms(31).

Omic strategies have aided the translation and application of genomic knowledge to the bedside. Transcriptomic analysis has been utilized as a part of a systems-based approach, helpful in understanding complex biological processes (24). An example is the transcriptome application for precision medicine approaches in sepsis (25). Given the increased application of transcriptomics to various clinical conditions, this paper aims to explore its application in sepsis. Hence, this paper seeks to expand our knowledge of the application of the transcript to the study of sepsis. Specifically, this scoping review aims to examine peer review literature identifying the utilization of

transcriptomic information applied to clinical sepsis (2012-2021), including the exploration for enhanced sepsis biomarking using the transcript (26). The aim was to identify and assimilate the application of gene-expression data, thus highlighting existing gaps in knowledge.

## **2.2 Materials and Methods**

A scoping review was undertaken using relevant literature to provide evidence for the idea that gene expression methods are usefully applied to sepsis, allowing a systems-based analysis. The methodological framework for scoping reviews is outlined by Levac et al., (32), as well as the PRISMA-ScR reporting guidelines by Tricco and colleagues (33). A protocol was designed and registered on the Open Science Framework (<https://osf.io/3jbv2>). This is registered as an embargoed registration till the 30<sup>th</sup> of December 2022, with the associated project [osf.io/5c2wr](https://osf.io/5c2wr).

### **Identifying the research question**

The hypothesis was that transcriptional studies support the generation of a framework encompassing clinical perspectives of this complex process. Thus the following research question was formulated: How can gene expression data be exploited to capture the dynamic host-pathogen interactions in sepsis and translate these into clinical insights supporting a suitable sepsis framework?

### **Identifying suitable studies**

Information sources were peer-reviewed PubMed-indexed journals, with the strategic schematic search for sepsis undertaken using the PubMed database (<https://pubmed.ncbi.nlm.nih.gov/>). Filters included 'Books and Documents, Clinical Trial, Meta-Analysis Review, Systematic Review' for

2012-2022. Key terms used included Endotypes, Meta-analysis, Sepsis/Microbiology, and Bacterial Sepsis/Immunology. Septic Shock/genetics, Sepsis/virology, Coronavirus, Sepsis/etiology, Proteome, SARS-CoV-2, Toll-like Receptor/cytokines, Pediatric sepsis, Benchmarking, Transcriptome Sepsis.

### **Study selection**

For inclusion, articles were required to meet the following criteria: (1) specific to the context of sepsis, (2) studies in humans, and (3) published from 2012 to 2022. Articles were excluded if they were: (1) conference abstracts and articles where full-text was not accessible or available; or (2) articles were published before 2012. Articles were excluded if the full text was not accessible, as information could not be extracted for further analysis.

The database search elicited 14,048 studies (see Figure 1). Keywords and or mesh terms were applied as single terms or Boolean string search combinations, generating 36 studies. The following subgroups were identified, sepsis definition, classification, severity, potential molecular biomarkers, and sepsis mortality (Figure 1). Literature was analyzed concerning the specific use of the transcript and its application to sepsis. The research team (AR & PAC)) independently screened the titles and abstracts of the 17 articles chosen to test their agreement. All disagreements were discussed for a consensus to be achieved. Pertinent

information concerning the application of transcript studies to sepsis was then recorded.

### **Charting the data**

A data extraction form was developed in Microsoft Excel by the researcher (AR). A single person (AR) extracted data from the full-text articles to ensure consistency. Extracted data contained the following information: population and study characteristics (demographics, aim, transcript information, genes of significance, study outcomes, and conclusions).

### **The collation and reporting of the results**

Extracted data was analyzed using descriptive quantitative and qualitative approaches. Descriptive quantitative analyses included summarizing the number of articles based on the data collection method. This allowed all papers to be classified into five categories (described in detail in the results section). A description of the transcript's relationship to key sepsis observations shall then be documented.

## Results

### 2.3. Sepsis Definition - Sepsis Beginnings?

An inflammatory cascade termed Systemic Inflammatory Response Syndrome (SIRS) was initially thought to be the first phase of Sepsis, followed by anti-inflammation (28). However transcriptomic analysis suggests this interpretation to be simplistic. For example, Bauer et al. (2016) showed that anti-inflammatory and immunosuppressive transcript biomarkers improve infection diagnosis and outcome prognostication(29). Possibly anti-inflammatory responses and defective adaptive immune reactions occur in unison. Thus suggesting an overlap of anti-inflammation with compromised adaptive immune response. A vital leap occurred when Sepsis was redefined in the 2016 third international consensus definitions for sepsis and septic shock, known as ‘Sepsis-3’(30). Here a dysregulated host immune response was a critical differentiator between infection and sepsis, with sepsis resulting in organ dysfunction. Other aspects important concerning the development of sepsis include sepsis genetic susceptibility from mendelian single-gene mutations as directly causing a susceptible host to more subtle multi-factorial determinants involving genetic variants and gene polymorphisms(31).

A systematic review and meta-analysis by Karakike et al. (2021) confirmed the majority of coronavirus disease 2019 patients hospitalized in the ICU setting met Sepsis-3 criteria(34). Providing evidence for the potential overlap between SARS-CoV2 and bacterial sepsis, Sohn et al. (2020) studied Covid-19-related Toll-like receptor-4-mediated signaling from peripheral blood mononuclear



cells (PBMCs) (35). Here patients with Covid-19 showed TLR-4 activation mediated signaling, similar to that observed with bacterial sepsis, suggesting that the innate host response is pathogen agnostic. Further, like bacterial sepsis, Covid-19 has also been described as a dysregulated process(36). Moreover, Barh et al. (2020) also showed that transcriptome studies from pulmonary tissue after SARS-CoV2 infection shared pathways with bacteria, parasites, and protozoa (37).

In another approach to characterize immune changes in sepsis, Schaack et al. (2018) gathered a meta-expression dataset from 949 microarray samples of patients with early sepsis (38). Two distinct clusters were found, one large (655 patients) and one minor (294 patients). When each group was compared to healthy controls, the larger cluster showed stronger dysregulation indicating both T-cell and monocyte function loss and granulocytic neutrophil activation. Suggesting immunosuppression, independent of the infectious disease process, occurs early in sepsis. Additionally, literature shows that immunosuppressed patients are less likely to die from an episode of bacteremia (39). Also, in characterizing bacterial sepsis according to cell types, Reyes et al. (2020) employed scRNA-seq analyses and found 16 immune cell states based on clustering of their gene expression profiles(40).

Further, a CD14+ mono state was identified and validated. Another challenge in defining sepsis is the need to compensate for host heterogeneity. For example, Wyn et al. (2011) compared transcriptomic responses in

different childhood subgroups, including neonates, infants, toddlers, and children of school age (41). Neonates with septic shock showed reduced gene expression of critical pathways associated with the innate and adaptive immune response. This was in contrast to the mainly unregulated transcriptome of the other groups.

## **2.4 Sepsis Classification**

### **2.4.1 Classification According to Sepsis Associated Organ Dysfunction**

Classifying patients with sepsis can be beneficial for applying principles of precision medicine. In one approach, transcript analysis correlates to organ dysfunction in sepsis, for example, concerning sepsis-associated acute kidney injury (SA-AKI)(42). Here the risk of children developing SA-AKI was successfully predicted from an increased expression using a 12 gene panel (43). Chew et al. (2018) showed the importance of noncoding RNAs (ncRNAs) as key regulators in inflammatory signaling in sepsis-related cardiac dysfunction (44). Beltran-Garcia et al. (2021) further showed that cardiac dysfunction reflects patterns of ncRNA expression (45).

## 2.4.2 Enrichment and Endotype Classification in Sepsis

Sweeney et al. (2015) found 11 genes that differentiated infectious from sterile inflammation, of which five were under-expressed (KIAA1370, TGFBI, MTCH1, RPGRIP1, and HLA-DPB1) and 6 were over-expressed (CEACAM1, ZDHHC19, C9orf95, GNA15, BATF, and C3AR1)(46). This 11-gene panel was also tested on three cohorts with neonatal sepsis against neonatal controls, showing areas under the ROC curve (AUC) of 0.92 - 0.93, i.e., highly predictive(47). Further, Sweeney et al. developed a bacterial versus viral classifier consisting of 7 genes(48). Genes IFI27, JUP, and LAX1 showed up-regulation in viral infections, and genes HK3, TNPIP1, GPAA1, and CTSB were up-regulated in bacterial infections. All genes, except GPAA1, have been linked to leucocyte activation. Also, a two-gene transcript signature (FAM89A and IFI44L) could distinguish patients with bacterial from a viral infection with 100% sensitivity and 96.4% specificity(49) validated in children with a mean age of 19 months. This 2-transcript RNA signature was also helpful in infants younger than 60 days of age, with a sensitivity of 88.8% and specificity of 93.7%(50). Further, in 4 cohorts, this 11-gene panel effectively separated septic trauma patients from matched non-infected trauma patients.

Other patient classification methods exist, for example, according to microbial characteristics based on gram staining. Cernada et al. (2021) differentiated patients with gram-positive versus gram-negative neonatal sepsis using transcript patterns(51). Using blood samples from septic infants with very low birth weight (VLBW), 21 genes were shown to be

significantly differentially expressed. In another method for Sepsis categorization, leucocyte transcriptome profiling of patients is possible. In this method, Leite et al. (2021) combined transcriptome data from leucocytes combined with proteomic analysis in sepsis patients versus controls (52). In so doing, they identified 122 co-differentially expressed genes/proteins showing gene expression trends.

Wong et al. (2019) advocated enrichment strategy, allowing the sub-classification of patient groups according to specific criteria, clinical, physiological, or biological characteristics, including response to treatment or other outcome measures (53). This enrichment approach using unsupervised transcriptomic clustering to define patient sepsis endotypes has been repeated across other studies (Table 1). Endotype grouping was similar, with SRS1 and MARS1 being associated with gene repression in innate and adaptive immune mechanisms. SRS1 and SRS2 subgroups were found in a prospective study of septic patients (54). In all of the studies, sub-group differences strengthen the relevance of the sub-grouping strategy undertaken. Using the transcript to define endotypes was taken further by simplifying the original analysis by using only four genes to determine endotype A or endotype B(55). Endotype A was associated with down-regulation of glucocorticoid receptor signaling, with corticosteroids being associated with a four-fold increase in mortality. Further, endotype switching was noted during sepsis, with the persistence of the Endotype A label consistent with a poor outcome (56). Ma et al. (2021)

used transcriptomic analysis to differentiate patients with sepsis-induced Acute Respiratory Distress Syndrome (ARDS) from non-sepsis-induced ARDS(57). Also, functional enrichment analysis demonstrated an altered immune response in sepsis-induced ARDS. Further, using protein-protein interaction network analysis, the TOP2A gene was identified as a critical regulator in sepsis-induced ARDS.

Using the Sequential Organ Failure Assessment (SOFA) score, Meidert et al. compared septic patients with controls to describe molecular networks (58). Criteria included hypoxia, impaired Glasgow Coma Score, circulatory failure, a low platelet count, and increased serum creatinine and bilirubin. This study identified 82 miRNAs and 3254 mRNAs as differentially expressed between sepsis and control patients. Also, 76 mRNA's and six miRNA transcripts specific to SOFA criteria were identified. Additionally, specific signaling networks were identified, suggesting a biological basis for the SOFA score.

## **2.5 Genes as markers of disease severity and role in prognostication**

Aschenbrenner et al. (2021) looked at the whole blood transcriptome of Covid-19 patients. Using this, they could stratify Covid-19 patients according to neutrophil signatures (36). Here, enrichment in Neutrophil activation-associated signatures was noted in patients with severe Covid-19, showing pronounced neutrophil-related alteration. Gene enrichment strategies have been employed in sepsis studies, combining clinical information with an understanding of the disease mechanisms(59). This strategy has also been suggested for Sepsis-Associated AKI (SA-AKI) studies where gene-expression biomarkers have had modest clinical value. (60). As such, enrichment methods show value in clinical-end-point-risk-stratification. Like in Gene enrichment, the endotype classification may also be useful from a disease severity and outcome perspective. For example, Baghela et al. (2022) classified patients according to five distinct endotypes(61). They also elicited a sepsis gene signature predicting organ dysfunction and mortality, lacking a determinate relationship with disease severity. In a study of patients with community-onset sepsis, a 30-day mortality prediction model generated using transcriptomic data from 16 studies demonstrated AUROCs from 0.765 to 0.89(62).

Gene expression studies have shown value in eliciting genes associated with sepsis mortality. Using sepsis datasets containing survival data, Feng et al. characterized 'survival DEGs' (63). Then mapping onto the protein-protein interaction database known as STRING, Feng et al. listed genes related to

S1PR3. A set of S1PR3 survival-related molecular signature genes (S3MS) were then characterized. Subsequently, a sepsis score based upon S3MS was statistically discriminatory between non-survivors and survivors. Also focusing on mortality in sepsis, Giannini used a DEG approach on 161 adult patients with 36% mortality (64). Subsequently, they showed gene enrichment across T-lymphocyte pathways resulting in dysregulation in the host's innate adaptive immune response.



## **2.6 mRNA Biomarking**

Using mRNA biomarkers from earlier work, Wong et al. (2012) combined these with plasma protein biomarkers to improve sepsis outcome prediction(65). A five-protein decision tree for sepsis outcome prediction was validated(PERSERVERE). Using these identified five proteins, combined with four mRNA biomarkers, Wong et al. (2017) were able to increase the predictability of 28-day sepsis mortality, improving the area under the receiver operating characteristic [AUROC] curve from 0.78 to 0.91 (PERSERVERE-XP model)(66).

## **2.7 Benchmarking Clinical Sepsis using the transcript, with therapeutic implications**

Benchmarking allows the comparison of processes against agreed standards (67). For example, the provision of physiological benchmarks was welcomed through the early pediatric sepsis definitions(11). This aided the development of a common communication framework that has been instrumental in transmuting coordinated sepsis global research efforts. Such as that exemplified by the Pediatric Taskforce on sepsis categorization (68). In a benchmark development and comparison strategy, Joachim et al. (2018) hypothesized that children demonstrated a relative resistance to mortality compared to adults, which they suggested represented a resistance effect measurable using transcriptome analysis(69). They identified age-associated differences in pathway activity generating four clusters—the construction of pathway drug networks correlated to survival in children and adults. Then, a benchmarking exercise was undertaken in the same study, comparing drug-disease relationships generated using Pathway Drug Network against curated, known drug-disease associations from two national databases. Next, challenging the networks resulted in drug leads with 10 of the top-ranked compounds tested for survival effects in an endotoxin model. Consequently, five of the ten compounds identified improved survival. Another benchmarking approach entails the recognition of transcriptomic fingerprints and having these available for other researchers to interpret blood gene expression profiles (70, 71). Sweeney et al. (2017) showed the value of using

public gene expression datasets for benchmarking purposes (72). They identified three gene expression classifiers for their ability to discern sepsis from non-infectious inflammation. They were applied to 39 datasets from publicly available data pertaining to a collective of 2604 patients. This research on whole blood time-matched showed AUC between 0.73-0.82, comparing non-infectious inflammation from sepsis datasets. Further, this analysis highlighted the challenge of identifying classifiers and then generalizing them to other studies. For example, when acute infection was compared to sepsis or healthy controls, one classifier, 'Septicyte Lab,' performed worse, showing AUCs  $< 0.7$  in 43% of cohorts. Mean validation areas under the receiver operating characteristic curve for discriminating septic patients from patients with noninfectious inflammation for the Sepsis MetaScore, the FAIM3-to-PLAC8 ratio, and the Septicyte Lab were 0.82 (range, 0.73-0.89), 0.78 (range, 0.49-0.96), and 0.73 (range, 0.44-0.90), respectively. Eight datasets had information about pathogen type, and here two classifiers, 'Sepsis MetaScore' and 'FAIM3:PLAC8 ratio', showed a significant difference ( $P < 0.05$ ) when viral infection was compared to bacterial infection, unlike the 'Septicyte Lab.' Amongst the three classifiers, a lack in the difference between gram-negative and gram-positive infection in 9 datasets was suggested as related to non-correction for confounding factors such as differences in microarray types or clinical circumstances.

## 2.8 Discussion

This scoping review aimed to understand the relationship of transcriptomic analysis to different aspects of clinical sepsis. In particular, it is hoped that transcriptomic analysis can shed light on sepsis pathogenesis in the acute phase. Particularly with sepsis often being described as a ‘dysregulated process.’ Understanding the nature of this dysregulation from an immunological perspective could pave the way for future therapeutic strategies. Consequently, this review of the application of the transcript to sepsis elicited categories related to diagnosis, definition, classification, bio-marking, and benchmarking. Transcriptomic analysis was applied to various aspects of sepsis diagnosis and provided molecular insights which might be necessary for the sepsis definition. Further, the role of the transcript in different elements of sepsis classification was outlined, and its use as a bio marking tool. Finally, the ability to benchmark immunological aspects of the septic process was evaluated. An important secondary goal was to understand the value of the transcript in providing a systems-level framework for improving sepsis management through knowledge developed in critical aspects of sepsis.

Pinnacle to developing the field of sepsis agrees upon a correct definition. The ideal definition encompasses the need for early clinical diagnosis, effective intervention, and improved outcomes. The term ‘sepsis’ has typically been synonymous with a bacterial infection. However, other infectious etiologies can result in sepsis. A case to point is the SARS-CoV-2 pandemic. For example, Karakike et al. (2021) showed that Sepsis-3 definitions apply to SARS-CoV2 sepsis (34). Also, there is the suggestion that viral and bacterial sepsis share TLR-4 activation pathways (35). This points to the role of transcriptomic analysis in understanding disease mechanisms, possibly aiding the fashioning of an enhanced definition of

sepsis. Barh work in pulmonary studies showed that SARS-CoV2 infection shared pathways across different organisms, including bacteria, prosoma, and parasites(37). This reinforces the idea of a pathogen-independent route to immune activation resulting in sepsis.

A transcriptomic understanding could help understand pathogenic differences and their consequent effects on host genomic, proteomic and metabolic pathways.

Thereby transcriptomic analysis could be vital in creating a sepsis definition incorporating diverse pathogen-initiating disease mechanisms. Hamilton's work in immunosuppression and bacteremia opens the question of the relationship of immunosuppression to the subsequent development of sepsis (39). Work by Reyes et al. shows the promise of transcriptomic analysis using scRNA-seq methods to document cellular changes, providing clarity of the dysregulated process in sepsis(40). Research by Wynn et al. showed the importance of considering age differences when documenting m-RNA responses (41). Another approach to the definition of sepsis, independent of the understanding mechanism of the disease, is to label sepsis according to the development of certain gene expression patterns or signatures. Hereby Reyes et al. (2020) showed the possibility of seeking a transcriptomic signature in bacterial sepsis (40). Thus providing an opportunity to label different sepsis types according to a sepsis definition. In a step to show functional immunological changes. Schaack et al. showed the clustering of a large cohort of sepsis patients into groups according to functional changes with functional loss in T-cells, Monocytes, and the activation of Neutrophils (38). Ideally, the definition should aid in the interface between immunological and physiological. The transcript analysis might also allow the ability to ensure the limits to a suitable sepsis definition. For example, Hamilton's work showed that the idea that

immunosuppression leads to morbidity in sepsis is simplistic, given their immunosuppressed cohort was less likely to die from sepsis (39).

## **CLASSIFICATION**

Using gene-expression information allows patient classification and categorization despite the challenges of organ dysregulation in sepsis. As such, transcript analysis has shown value in studying SA-AKI (42, 73). Also, the role of matching physiological dysfunction to gene expression was noted to be possible in sepsis-associated cardiac dysfunction (45). Other classification methods exist, including bacterial versus viral grouping, septic versus non-septic trauma, gram-positive versus gram-negative sepsis, and leucocyte profiles. An endotype strategy has been used by researchers (Table 1). Scoring systems such as the well-established SOFA score help predict the outcome. Meidert et al. used a miRNA and mRNA gene expression to subgroup according to specific SOFA criteria(58). Other classifications include ARDS versus non-ARDS (57). Transcript classification according to disease severity may be possible. For example, covid-19 patients were stratified by Aschenbrenner et al. (2021) using neutrophil signatures(36). Cardiac dysfunction, a significant complication of sepsis, has been studied using transcriptomic analysis (44, 45). This re-iterates the future potential value of transcriptomic analysis in assessing sepsis complications. Cernada et al. 2021 showed that genes linked to cell survival and cytokine production were associated with improved survival from gram-positive bacterial infection(51). An essential application of transcriptomics is validating established clinical tools such as the SOFA score by Meidert et al. (58). Thereby providing an objective link between the transcript and clinical application. Such insights could have several uses, one being

the application of precision strategies to affect biological mechanisms through the linkage of the SOFA score to changes in gene expression.

## **SEVERITY & MOLECULAR BIOMARKING**

The use of transcriptomic strategies applied to disease stratification was illustrated by Odum (2021) et al., using gene enrichment. Gene enrichment allows combining clinical information with an understanding of disease mechanisms. Future endotype classification may also allow categorization according to disease severity and outcome(61). Given the critical role of white cells in the innate response to sepsis, analysis of the white cells in this regard provides an important perspective. Accordingly, Enriched neutrophil transcript signature from Covid-19 patients allowed stratification of Covid-19 patients (36). Sweeney et al. (2018) collated data from 16 studies developing a mortality prediction model(62). Also, survival DEG panels useful for mortality prediction have been presented (63, 64). Wong et al. developed a combination of plasma protein biomarkers combined with mRNA biomarkers to improve mortality prediction(66).

## **BENCHMARKS**

Finally, the challenge in sepsis is applying benchmarks using transcriptomic data, given the heterogeneity inherent in the host-pathogen interaction (22). Joachim (2018) tested the value of benchmarking using transcription analysis comparing adults with children to develop benchmarks(69). Thus illustrating the value of a transcriptomic approach to benchmarking and generating drug leads. These were then used to identify compounds tested using an endotoxin model. The idea of creating a transcriptomic fingerprint library for future benchmarking has been presented(70-72).

Analysis of transcript data has numerous limitations, including the portability of insights from one RNA-based study to another. Many reasons exist for



this, including heterogeneity caused by different platform types, the timing of specimen collection, and host-pathogen differences, including demographic differences such as age. For example, chronological aspects of the immunological response to acute sepsis remain ambiguous. Also, sequential tracking of immune changes in sepsis is rudimentary, with clinical reliance on biomarkers that are analyzed clinically daily. Thus the inability to track immune changes across shorter time durations. Further, making sense of sepsis pathogenesis is fraught with difficulties inherent due to multiple host and pathogen factors, resulting in heterogenic complexity. A limitation concerning the clinical literature is the lack of temporal transcriptomic clinical studies, which highlights a gap in the clinical literature.

We believe this review to be unique in showing the possibility of using transcriptomic information to help piece together areas critical to the understanding and application of clinical sepsis. Further, the scoping review showed that to make sense of sepsis pathogenesis, given the dynamic nature of the condition, the use of gene expression data might be helpful. Moreover, the mRNA signal is not a constant feature, changing according to the milieu of the cell. This might make the transcript useful in indicating changes in genes and, thus, cellular function. Hence, as a part of the systems approach, transcript information would be related to cellular changes from which deductions as to effects at the organ level could then be deduced. Insights thus gained could drive our understanding of sepsis. Achieving a temporal sense of changes according to gene function inferred from gene expression data requires a multi-time sequence collection of blood samples. This assumes that mRNA gene expression data incorporates time-associated changes. However, this review paper highlights the lack of temporal sepsis studies in clinical sepsis, underlying a notable

gap in the literature.

.

.

## **2.9 Limitations**

Analysis of transcript data has numerous limitations, including the portability of insights from one RNA-based study to another. Many reasons exist for this, including heterogeneity caused by different platform types, the timing of specimen collection, and host-pathogen differences, which include demographic differences such as age, etc. For example, chronological aspects of the immunological response to acute sepsis remain ambiguous. Also, sequential tracking of immune changes in sepsis is rudimentary, with clinical reliance on biomarkers that are analyzed clinically on a daily basis. Thus the inability to track immune changes across shorter time durations. Further, making sense of sepsis pathogenesis is fraught with difficulties inherent due to multiple host and pathogen factors, resulting in heterogenic complexity.

## **2.10 Conclusion**

In this study, an analysis of the RNA transcript and its biological application to sepsis was undertaken. It was shown that transcriptomic information is applicable in enhancing sepsis understanding. Uses of transcript analysis in sepsis research were illustrated, including diagnostic, therapeutic profiling, and prognostication in clinical sepsis. Gene expression approaches showed value in disease classification and outcome prognostics, which could then be usefully applied to understand sepsis pathogenesis and influence clinical guidelines. Further, as computer accessibility increases and scientists develop novel techniques to deliver high throughput gene expression at the bedside, transcriptomic technologies could become more relevant in precision medicine strategies. Therefore, an opportunity to use transcriptomic information to further our interpretation of sepsis exists. Therefore seeking a transcriptomic interpretation directs future developments of sepsis definitions and protocols. Hence enabling improved sepsis-associated outcomes through enhanced therapeutic precision. This could help influence the development of a new direction for novel therapeutics.

## **2.11 Funding**

No Funding requirements

## **2.12 Author Contributions**

Conceived and designed the methodology: AR

Performed the experiments: AR

Analyzed the data: AR, PAC

Contributed analysis, methods, and tools: AR

Wrote the first draft of the paper: AR

Supervision: MGS, AA,AH


Revised critically for importance and intellectual content: AR,KW, HA, BH,PK,AS,CK, BSB, MT, ZH, HV, GB, ZM, RN, RM, SD, NK, RK, AS, PW, MGS, JS, SAZ, RP, MT, WZ, MAZ, HS, AA, AH

## **2.13 Data Availability**

All cited literature has been used for this scoping review and is available as per the references provided according to journals in the public domain.


## **2.14 Acknowledgements**

Making sense of the unknown, in remembrance of Professor Hector Wong, a pioneer in the field of transcriptomics of sepsis



**Figure 1.** The strategic schematic search for sepsis is done using PubMed database (<https://pubmed.ncbi.nlm.nih.gov/>). The physiologic, pathologic, and biochemical abnormalities of sepsis incidence have been thoroughly reviewed using key terms and mesh terms, that could be applied in the search alone or in combination. Multiple trials have been expected in order to search for recent and relevant studies. Filter types have been applied to deduce the number of search (n=14,048). Studies from ten years ago up to recent have been selected. Titles and abstracts of potentially qualifying research are reviewed to further deduce the selection, followed by full-texts and content methodology. Any study that focuses on the prevalence of sepsis or septic shock, as well as some recent clinical trials in any community have been considered (n=36). Successful searches have been made for sepsis definition, classification, severity, potential molecular biomarkers, and sepsis mortality. Note that Kaforou et al., (2017)(50) was using the dataset of Mahajan et al., (2016, NCBI Accession dataset GSE64456) (74)-this has been counted as two separate studies.

**Figure 2.** Application of a Systems-based Approach using the Sepsis Transcript to Structure Sepsis Guidelines.



**Figure 2.** The application of the transcriptome to enhance the backbone of understanding required to enhance sepsis guidelines is shown. Herein, such host factors as age and timing of infection may be pertinent. Clinical consequences of sepsis, if unabated, resulting in severe organ dysfunction. Eventually leading to physiological instability and septic shock. Single-organ dysfunction in sepsis is rare, with the subsequent failure of each organ being associated with an increased risk of a poor outcome(27). Further, the relationship between organ failure and the development of Multi-Organ Dysfunction Syndrome (MODS) is of interest. The application of transcriptional

information to various aspects of sepsis requires consideration. There is interest in the correlation of the transcript to the immune response and host susceptibility to infection. One study area is the relationship of disease subtypes according to distinct pathophysiological mechanisms, also known as Endotypes. The relationship of biomarkers to gene expression is of particular interest, especially from a temporal perspective. Finally, the transcript may have value in benchmarking sepsis, such as correlating to clinical variables and end-points, in the development of prediction tools such as biomarkers. Also, the transcript may be used to follow disease progression using various analytical tools. An essential aim of the transcriptomic analysis is to improve the application of clinical therapies in a more precise approach, mindful of host-pathogen complexity. mRNA is thus vital for cellular function and consists of mRNA protein-coding and non-protein-coding RNA functions. The two facets allow mRNA to have a role in gene code translation for protein synthesis and a gene regulatory role. Essentially, mRNA is the genetic mediator guiding ribosomal protein synthesis based upon information provided in the DNA. At this moment, transcriptomics aims to document gene activity by quantifying mRNA, analyzing gene expression patterns, and measuring gene levels seen in sepsis. Gene to gene connections are shown, with genes illustrated as nodes. The interconnections between the genes then, represent the regulatory



relationship. Therefore the network interactions amongst the genes form a Gene Regulatory Network (GRN).

**Table 1: Endotyping from Transcript Clustering in Critically ill Sepsis Patients**

Country	Main Finding	n	Number of Endotypes	Endotype Classes & Mortality (%)	Endotype Functional Characteristics	Treatment Response Testing according to Endotype	Reference
USA	Endotype Identified in children with sepsis	98	Three endotype subclasses identified (Endotype A-C)  Endotype A (29%) Endotype B (46%) Endotype C (26%)	28-day Mortality  Endotype A (36%) Endotype B (11%) Endotype C (12%)	Endotype A demonstrating the most deranged signaling pathways, with genes repressed associated with the glucocorticoid receptor signaling, the adaptive immune system and zinc homeostasis. Also both the degree of organ failure and illness severity was highest in endotype A, and also age being the youngest in endotype A.	Testing not undertaken	(75)
USA	Differential response to sepsis corticosteroids according to Endotype in children with sepsis	168	Endotype A (34-48%) Endotype B (52-66%)	28-day Mortality  Discovery Cohort Endotype A 21% Endotype B 10%  Validation Cohort Endotype A 17% Endotype B 5%	Subclass A displayed higher median PRISM scores, were younger. Also this Endotype demonstrated lower proportion comorbidity compared to Endotype subclass B. Also patients in subclass A showed a lower total white blood cell and absolute neutrophil counts, however with a higher absolute lymphocyte counts, compared to Endotype subclass B patients. Endotype A patients had a higher mortality and complicated course compared to subclass B patients.	Endotype A patients showed an increased mortality in association with corticosteroid therapy	(76)
UK	Endotypes identified in Adult ICU patients with sepsis due to community-acquired pneumonia (CAP)	265	Transcriptomic profiling defined two sepsis response signatures SRS1 (35-41%) SRS2 (59-65%)	28-day mortality SRS1 SRS2  Discovery Cohort SRS1 27% SRS2 17%  Validation Cohort SRS1 65% SRS2 41%	SRS1 category being associated with switching from oxidative phosphorylation to glycolysis, endotoxin-tolerance, relative immunosuppression, human leukocyte antigen (HLA) class II repression and T-cell exhaustion.	Testing not undertaken	(77)
UK	Differential response to sepsis corticosteroids & mortality (SRS2) according to Endotype in adults with sepsis	176	SRS1 (47%) SRS2 (53%)	SRS1 (33-37%) 37% Placebo Group 33% Steroid Group SRS2 (8-42%) 8% Placebo group 42% Steroid Group	The first time SRS1 and SRS2 Endotypes described in sepsis patients from multiple different infection sources.	Increased mortality is noted in the SRS2 group in association with hydrocortisone treatment	(56)
Netherlands and UK	Differential response to sepsis corticosteroids according to Endotype in adults with sepsis	306	Four endotypes (Mars1-4) Mars1 (13-29%) Mars2 (34-44%) Mars3 (23-37%) Mars 4 (6-13%).	28-day mortality Mars1 (39%) Mars2 (22%) Mars3 (23%) Mars 4 (33%).	The Mars1 poor-prognosis endotype had an increase in expression of cellular metabolic pathways (heme biosynthesis) and a decrease in expression of genes involved in adaptive and innate immunity (nuclear factor-κB signaling [NF-κB], antigen presentation, Toll-like receptor, antigen presentation, and T-cell receptor signaling).  Mars2 and 4 endotype showed up-regulation of cytokine pathways (inducible nitric oxide synthase, interleukin [IL]-6, interferon signaling, NF-κB) and pattern recognition, associated with hyperinflammation.  Mars3 the endotype with the lower-risk for mortality showed increased expression of adaptive immune pathways (natural killer cells, IL-4 signaling, T-helper cells, B-cell development). Further, a two-gene expression ratio was derived enabling endotype classification on ICU admission.	Testing not undertaken	(78)
USA/SPAIN	Multiple Studies	700	Three response clusters	30-day mortalities into three groups  30% Inflammopathic 8% Adaptive	<b>Inflammopathic</b> increased innate and reduced adaptive immune signal as suggested by complement activation, increased expression of IL-1 receptor, pattern recognition receptor activity)	Testing not undertaken	(79)

				25% Coagulopathic	<b>Adaptive</b> Reduced innate and high adaptive immune signal, showing interferon signaling) <b>Coagulopathic</b> Irregularities in the coagulation and complement systems, including glycosaminoglycan binding and platelet degranulation.		
--	--	--	--	----------------------	---	--	--

**Table 2: Summary of Literature generated for the Scoping Review**

**Definition**

Author	Country	Objective	Study Design	Participant/Target Population	Sample Size
Karakike 2021(80)	European Group	Focused on the prevalence of viral sepsis in patients with Covid-19.	A systematic review and meta-analysis	COVID-19 patients with sepsis and organ dysfunction	3,825 articles searched, 151 were analyzed, with only five reporting sepsis prevalence.
Barh 2020(37)	India	Illustrate biological events associated with SARS-CoV-2 infection and the identification of drug candidates.	A secondary Multi-omics analysis of peer-reviewed public datasets	SARS-CoV-2 Infection from 5 data sets	332 human proteins, 88 upregulated transcripts, 1067 upregulated genes from COVID-19 patients' blood, 136 upregulated human proteins of Caco-2 cells, and 745 genes associated with COVID-19
Sohn 2020(35)	Korea	Characterise the immune response in critically ill patients, including those with COVID-19.	A Prospective cohort study	COVID-19 patients	8 severe and 20 mild COVID-19 patients
Schaack 2018(38)	Germany	Whole blood transcriptomic analysis of adult patients with early in the sepsis episode.	A systematic review and meta-analysis	Adult patients with sepsis admitted to ICU from 135 GEO and 75 ArrayExpress studies	949 septic patients and 135 healthy controls
Reyes 2020(40)	USA	Blood profiling of sepsis patients using scRNA-seq technology.	A cohort study	UTI patients with and without sepsis	29 sepsis patients and 36 controls
Wynn 2011(41)	USA	Identification of gene expression across different aged neonates with septic shock.	A cohort study	10 years of age children with septic shock	1

## Classification

Author	Country	Objective	Study Design	Participant/Target Population	Sample Size
Hasson 2021(42)	USA	To document the current understanding of sepsis associated Acute Kidney Injury Pathophysiology using Omic interpretations	A Narrative Review	SA-AKI patients	NA
Basu 2011(73)	USA	Microarray analysis to identify biomarkers for severe septic shock-associated kidney injury.	Observational Cohort Study	Septic-shock-associated acute kidney injury (SSAKI) patients	179 children with septic shock and 53 controls
Chew 2018(44)	Singapore	To describe the mechanisms and functions of ncRNAs in the regulation of inflammatory signaling.	A Narrative Review	NA	NA
Beltran-Garcia 2021(45)	Spain	Describe the importance of non-coding RNAs mechanisms in cardiovascular dysfunction associated with sepsis.	A Narrative Review	Patients with sepsis and cardiovascular dysfunction	NA
Sweeney 2015(46)	USA	To describe publicly available sepsis gene data sets to achieve robust set of genes for to differentiation patient with sepsis from those with sterile inflammation.	Multicohort study using secondary analysis of Publicly Archived available data.	Gene expression microarray of acute infections from 20 cohort	1057 samples of bacterial and viral infection
Sweeney 2017(72)	USA	Test gene classifiers (11-gene 'Sepsis MetaScore', the Septicyte Lab and FAIM3:PLAC8 ratio) on sepsis datasets.	Multicohort study using secondary analysis of Publicly Archived available data.	Sepsis and acute infection from 39 datasets	3,241 whole blood samples from 2,604 patients
Sweeney 2016(48)	USA	Multicohort analysis to derive a set of seven genes for robust discrimination of bacterial from viral infections.	Multicohort study using secondary analysis of Publicly Archived available data.	Gene expression of sepsis from 27 datasets	663 samples from five datasets with 11 genes expressed
Herberg 2016(49)	London	Describe blood RNA expression signature allowing the differentiation of bacterial versus viral infection in febrile children.	A Prospective Cohort Study	Febrile children from the hospitals in UK, Spain, Netherlands and USA	240 patients including 189 from UK, 16 from Spain, and 35 from USA
Kaforou 2017(50)	UK	Distinguishing children with potentially life-threatening bacterial infections from febrile	A retrospective study of the Mahajan Study data (see below)	Febrile infants	89 infants with bacterial infection and 111 with viral infections

		children with viral infections using applying a 2-Transcript Host RNA Signature.			
Cernada 2021(81)	Spain	Using transcriptomic profiles to discriminate between Gram-positive and Gram-negative bacterial sepsis in preterm neonates	A prospective, observational cohort study.	low birth weight infants with sepsis	25 septic preterm infants (17 with Gram-positive bacterial infection and 8 with Gram-negative bacterial infection)
Leite 2021(52)	Brazil	Using transcriptomic and proteomic profiling to understand interconnections between the genes and proteins in clinical sepsis.	A cohort study using a secondary analysis of two Publicly Archived datasets.	Whole blood and leukocytes of sepsis patients from two datasets	478 patients and 42 controls from GSE data, 46 patients and 10 controls from ArrayExpress
Meidert 2021(58)	Germany	Describe sequence of small non-coding miRNAs and protein-coding mRNAs from blood cells and the SOFA score in patients with sepsis.	A prospective, observational cohort study.	RNA profiles from patients with septic shock	A total of 54 septic shock patients
Burnham 2017(54)	Fill	Investigation of individual and temporal variations in the transcriptomic response to sepsis caused by fecal peritonitis.	A prospective, observational cohort study.	Sepsis patients in ICU	117 sepsis patients with fecal peritonitis, 126 community acquired pneumonia, and 10 controls
Antcliffe 2019(56)	UK	Describe transcriptomic endotypes associated with response to either norepinephrine or vasopressin, or to corticosteroids.	A prospective, observational cohort study.	Sepsis patients with varied response to steroids.	176 patients
Atreya 2019(82)	USA	Application of the principles of precision medicine to pediatric sepsis.	Narrative Review.	Pediatric sepsis	NA
Mahajan 2016(74)	USA	Using the RNA bio signatures to diagnose infants aged 60 days or younger with fever with or without serious bacterial infections.	A prospective, observational cohort study.	febrile infants aging 60 days or younger	279 febrile infants (89 with bacterial infections, and 190 without bacterial infections), 19 healthy controls

## Severity

Author	Country	Objective	Study Design	Participant/Target Population	Sample Size
Feng 2021(63)	USA	To identify S1PR3 gene	Secondary	Sepsis-related	whole blood

		signature in the development of sepsis.	analysis of archived datasets.	genes from two datasets.	transcriptome of 35 survivors and non-survivors of sepsis.
Baghela 2022(61)	Canada	Using Machine Learning to identify clinical gene signatures associated with disease severity, mortality, organ dysfunction and according to endotypes/mechanisms.	Observational cohort study.	ER sepsis patients.	348 sepsis patients and 44 healthy controls.
Sweeney 2018(62)	USA	Prediction of sepsis using gene expression profiles.	A systematic analysis	Sepsis patients with acute infection from selected cohorts.	17 cohorts from public database (gene expression profiles of adults and children), 4 private cohorts (HAI)
Aschenbrenner 2021(36)	Greece and Netherlands	With many describing a dysregulated immune system with COVID-19, RNA-seq analysis is undertaken to characterize COVID-19 patients according to disease severity.	Observational cohort study.	COVID-19 patients	Patients admitted between March 13 and March 30, 2020 with 10 healthy controls, Second cohort includes 30 patients.

## Molecular Markers

Author	Country	Objective	Study Design	Participant/Target Population	Sample Size
Feng 2021(63)	Arizona	To identify S1PR3 gene signature in the development of sepsis.	Secondary Analysis of Archived Datasets.	Sepsis infection from two datasets.	Whole blood transcriptome data from 35 survivors and non-survivors of sepsis
Cosgriff 2021(64)	USA	Characterization of whole blood transcriptome in critical patients with and without sepsis.	Descriptive [Poster]	Whole blood transcripts from critical sepsis patients.	419 transcripts from 161 sepsis patients.
Stanski 2020(59)	USA	Review on the development of precision medicine in sepsis.	Narrative Review.	Sepsis studies.	NA
Odum 2021(60)	USA	Review on the current biomarkers for sepsis-associated acute kidney injury.	Narrative Review.	Pediatric sepsis.	NA



## REFERENCES

1. Xu C, Xu J, Lu L, Tian W, Ma J, Wu M. Identification of key genes and novel immune infiltration-associated biomarkers of sepsis. *Innate Immun*. 2020;26(8):666-82.
2. Zhou X, Wang Y, Chen J, Pan J. Constructing a 10-core genes panel for diagnosis of pediatric sepsis. *J Clin Lab Anal*. 2020:e23680.
3. Li Y, Li Y, Bai Z, Pan J, Wang J, Fang F. Identification of potential transcriptomic markers in developing pediatric sepsis: a weighted gene co-expression network analysis and a case-control validation study. *J Transl Med*. 2017;15(1):254.
4. Wong HR, Cvijanovich N, Allen GL, Lin R, Anas N, Meyer K, et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. *Crit Care Med*. 2009;37(5):1558-66.
5. Parnell GP, Tang BM, Nalos M, Armstrong NJ, Huang SJ, Booth DR, et al. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions. *Shock*. 2013;40(3):166-74.
6. Zhang S, Li N, Chen W, Fu Q, Liu Y. Time Series Gene Expression Profiles Analysis Identified Several Potential Biomarkers for Sepsis. *DNA Cell Biol*. 2020;39(10):1862-71.
7. Li M, Huang H, Ke C, Tan L, Wu J, Xu S, et al. Identification of a novel four-gene diagnostic signature for patients with sepsis by integrating weighted gene co-expression network analysis and support vector machine algorithm. *Hereditas*. 2022;159(1):14.
8. Yao Y, Zhao J, Hu J, Song H, Wang S, Wang Y. Identification of a Four-Gene Signature for Diagnosing Paediatric Sepsis. *Biomed Res Int*. 2022;2022:5217885.
9. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet*. 2020;395(10219):200-11.
10. Vandewalle J, Libert C. Sepsis: a failing starvation response. *Trends in Endocrinology & Metabolism*. 2022;33(4):292-304.
11. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric S. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med*. 2005;6(1):2-8.
12. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Medicine*. 2017;43(3):304-77.
13. Sprung CL, Trahtenberg U. What Definition Should We Use for Sepsis and Septic Shock? *Crit Care Med*. 2017;45(9):1564-7.
14. Souza DC, Brandao MB, Piva JP. From the International Pediatric Sepsis Conference 2005 to the Sepsis-3 Consensus. *Rev Bras Ter Intensiva*. 2018;30(1):1-5.
15. McGovern M, Giannoni E, Kuester H, Turner MA, van den Hoogen A, Bliss JM, et al. Challenges in developing a consensus definition of neonatal sepsis. *Pediatr Res*. 2020;88(1):14-26.
16. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. *Pediatr Crit Care Med*. 2020;21(2):e52-e106.
17. Sweeney DA, Danner RL, Eichacker PQ, Natanson C. Once is not enough: clinical trials in sepsis. *Intensive Care Medicine*. 2008;34(11):1955-60.

18. Martimbianco ALC, Pacheco RL, Bagattini AM, de Fatima Carreira Moreira Padovez R, Azevedo LCP, Riera R. Vitamin C-based regimens for sepsis and septic shock: Systematic review and meta-analysis of randomized clinical trials. *J Crit Care*. 2022;71:154099.
19. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. *Lancet Infect Dis*. 2015;15(5):581-614.
20. Berry M, Patel BV, Brett SJ. New Consensus Definitions for Sepsis and Septic Shock: Implications for Treatment Strategies and Drug Development? *Drugs*. 2017;77(4):353-61.
21. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. *Nat Rev Immunol*. 2017;17(7):407-20.
22. Leligidowicz A, Matthay MA. Heterogeneity in sepsis: new biological evidence with clinical applications. *Crit Care*. 2019;23(1):80.
23. Lorton F, Chalumeau M, Martinot A, Assathiany R, Roue JM, Bourgoin P, et al. Prevalence, Characteristics, and Determinants of Suboptimal Care in the Initial Management of Community-Onset Severe Bacterial Infections in Children. *JAMA Netw Open*. 2022;5(6):e2216778.
24. Fernandez-Sarmiento J, Schlapbach LJ, Acevedo L, Santana CR, Acosta Y, Diana A, et al. Endothelial Damage in Sepsis: The Importance of Systems Biology. *Front Pediatr*. 2022;10:828968.
25. Ruiz-Rodriguez JC, Plata-Menchaca EP, Chiscano-Camón L, Ruiz-Sanmartin A, Pérez-Carrasco M, Palmada C, et al. Precision medicine in sepsis and septic shock: From omics to clinical tools. *World J Crit Care Med*. 2022;11(1):1-21.
26. Massaud-Ribeiro L, Silami P, Lima-Setta F, Prata-Barbosa A. Pediatric Sepsis Research: Where Are We and Where Are We Going? *Front Pediatr*. 2022;10:829119.
27. Lelubre C, Vincent J-L. Mechanisms and treatment of organ failure in sepsis. *Nature Reviews Nephrology*. 2018;14(7):417-27.
28. Coopersmith CM, Amiot DM, 2nd, Stromberg PE, Dunne WM, Davis CG, Osborne DF, et al. Antibiotics improve survival and alter the inflammatory profile in a murine model of sepsis from *Pseudomonas aeruginosa* pneumonia. *Shock*. 2003;19(5):408-14.
29. Bauer M, Giamarellos-Bourboulis EJ, Kortgen A, Möller E, Felsmann K, Cavaillon JM, et al. A Transcriptomic Biomarker to Quantify Systemic Inflammation in Sepsis — A Prospective Multicenter Phase II Diagnostic Study. *EBioMedicine*. 2016;6:114-25.
30. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
31. Miranda M, Nadel S. Impact of Inherited Genetic Variants on Critically Ill Septic Children. *Pathogens*. 2022;11(1):96.
32. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation science*. 2010;5(1):1-9.
33. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of internal medicine*. 2018;169(7):467-73.
34. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, Fleischmann-Struzek C, Pletz MW, Netea MG, et al. Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2021;49(12):2042-57.
35. Sohn KM, Lee SG, Kim HJ, Cheon S, Jeong H, Lee J, et al. COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. *J Korean Med Sci*. 2020;35(38):e343.

36. Aschenbrenner AC, Mouktaroudi M, Kramer B, Oestreich M, Antonakos N, Nuesch-Germano M, et al. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. *Genome Med.* 2021;13(1):7.
37. Barh D, Tiwari S, Weener ME, Azevedo V, Goes-Neto A, Gromiha MM, et al. Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19. *Comput Biol Med.* 2020;126:104051.
38. Schaack D, Siegler BH, Tamulyte S, Weigand MA, Uhle F. The immunosuppressive face of sepsis early on intensive care unit-A large-scale microarray meta-analysis. *PLoS One.* 2018;13(6):e0198555.
39. Hamilton F, Evans R, Ghazal P, MacGowan A. Patients with transplantation have reduced mortality in bacteraemia: Analysis of data from a randomised trial. *Journal of Infection.* 2022;85(1):17-23.
40. Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. *Nat Med.* 2020;26(3):333-40.
41. Wynn JL, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, et al. The influence of developmental age on the early transcriptomic response of children with septic shock. *Mol Med.* 2011;17(11-12):1146-56.
42. Hasson D, Goldstein SL, Standage SW. The application of omic technologies to research in sepsis-associated acute kidney injury. *Pediatr Nephrol.* 2021;36(5):1075-86.
43. Basu RK. Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray. *Crit Care.* 2011;15.
44. Chew CL, Conos SA, Unal B, Tergaonkar V. Noncoding RNAs: Master Regulators of Inflammatory Signaling. *Trends Mol Med.* 2018;24(1):66-84.
45. Beltran-Garcia J, Osca-Verdegel R, Nacher-Sendra E, Cardona-Monzonis A, Sanchis-Gomar F, Carbonell N, et al. Role of non-coding RNAs as biomarkers of deleterious cardiovascular effects in sepsis. *Prog Cardiovasc Dis.* 2021;68:70-7.
46. Sweeney TE, Shidham A, Wong HR, Khatri P. A comprehensive time-course-based multicohort analysis of sepsis and sterile inflammation reveals a robust diagnostic gene set. *Sci Transl Med.* 2015;7(287):287ra71.
47. Sweeney TE, Wynn JL, Cernada M, Serna E, Wong HR, Baker HV, et al. Validation of the Sepsis MetaScore for Diagnosis of Neonatal Sepsis. *J Pediatric Infect Dis Soc.* 2018;7(2):129-35.
48. Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. *Sci Transl Med.* 2016;8(346):346ra91.
49. Herberg JA, Kaforou M, Wright VJ, Shailes H, Eleftherohorinou H, Hoggart CJ, et al. Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. *JAMA.* 2016;316(8):835-45.
50. Kaforou M, Herberg JA, Wright VJ, Coin LJM, Levin M. Diagnosis of Bacterial Infection Using a 2-Transcript Host RNA Signature in Febrile Infants 60 Days or Younger. *JAMA.* 2017;317(15):1577-8.
51. Cernada M, Pinilla-Gonzalez A, Kuligowski J, Morales JM, Lorente-Pozo S, Pineiro-Ramos JD, et al. Transcriptome profiles discriminate between Gram-positive and Gram-negative sepsis in preterm neonates. *Pediatr Res.* 2022;91(3):637-45.
52. Leite GGF, Ferreira BL, Tashima AK, Nishiduka ES, Cunha-Neto E, Brunialti MKC, et al. Combined Transcriptome and Proteome Leukocyte's Profiling Reveals Up-Regulated Module of Genes/Proteins Related to Low Density Neutrophils and Impaired Transcription and Translation Processes in Clinical Sepsis. *Front Immunol.* 2021;12:744799.

53. Wong H. Sepsis genomics and precision medicine. 2019(Boston: Academic Press):2019:83-93.
54. Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC, Hutton P, et al. Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. *Am J Respir Crit Care Med*. 2017;196(3):328-39.
55. Atreya MR, Wong HR. Precision medicine in pediatric sepsis. *Curr Opin Pediatr*. 2019;31(3):322-7.
56. Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial. *Am J Respir Crit Care Med*. 2019;199(8):980-6.
57. Ma J, Li Q, Ji D, Hong L, Luo L. Predicting candidate therapeutic drugs for sepsis-induced acute respiratory distress syndrome based on transcriptome profiling. *Bioengineered*. 2021;12(1):1369-80.
58. Meidert AS, Buschmann D, Brandes F, Kanev K, Billaud JN, Borrmann M, et al. Molecular RNA Correlates of the SOFA Score in Patients with Sepsis. *Diagnostics (Basel)*. 2021;11(9).
59. Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. *Nat Rev Nephrol*. 2020;16(1):20-31.
60. Odum JD, Wong HR, Stanski NL. A Precision Medicine Approach to Biomarker Utilization in Pediatric Sepsis-Associated Acute Kidney Injury. *Front Pediatr*. 2021;9:632248.
61. Baghela A, Pena OM, Lee AH, Baquir B, Falsafi R, An A, et al. Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures. *EBioMedicine*. 2022;75:103776.
62. Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, et al. A community approach to mortality prediction in sepsis via gene expression analysis. *Nat Commun*. 2018;9(1):694.
63. Feng A, Ma W, Faraj R, Kelly GT, Black SM, Fallon MB, et al. Identification of S1PR3 gene signature involved in survival of sepsis patients. *BMC Med Genomics*. 2021;14(1):43.
64. Giannini H, Cosgriff C, Lu X, Anderson B, Jones T, Miano T, et al. A Whole Blood Transcriptome Signature Implicates Dysregulation of Both Innate and Adaptive Immunity in Septic Shock. TP53 TP053 SEPSIS AND MULTIORGAN FAILURE: American Thoracic Society; 2021. p. A2721-A.
65. Wong HR, Salisbury S, Xiao Q, Cvijanovich NZ, Hall M, Allen GL, et al. The pediatric sepsis biomarker risk model. *Crit Care*. 2012;16(5):R174.
66. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP. *Am J Respir Crit Care Med*. 2017;196(4):494-501.
67. Weber LM, Saelens W, Cannoodt R, Sonesson C, Hapfelmeier A, Gardner PP, et al. Essential guidelines for computational method benchmarking. *Genome Biol*. 2019;20(1):125.
68. Menon K, Schlapbach LJ, Akech S, Argent A, Biban P, Carrol ED, et al. Criteria for Pediatric Sepsis-A Systematic Review and Meta-Analysis by the Pediatric Sepsis Definition Taskforce. *Crit Care Med*. 2022;50(1):21-36.
69. Joachim RB, Altschuler GM, Hutchinson JN, Wong HR, Hide WA, Kobzik L. The relative resistance of children to sepsis mortality: from pathways to drug candidates. *Mol Syst Biol*. 2018;14(5):e7998.

70. Chaussabel D, Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. *Nat Rev Immunol*. 2014;14(4):271-80.
71. Altman MC, Rinchai D, Baldwin N, Toufiq M, Whalen E, Garand M, et al. Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. *Nat Commun*. 2021;12(1):4385.
72. Sweeney TE, Khatri P. Benchmarking Sepsis Gene Expression Diagnostics Using Public Data. *Crit Care Med*. 2017;45(1):1-10.
73. Basu RK, Standage SW, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, et al. Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray. *Crit Care*. 2011;15(6):R273.
74. Mahajan P, Kuppermann N, Mejias A, Suarez N, Chaussabel D, Casper TC, et al. Association of RNA Biosignatures With Bacterial Infections in Febrile Infants Aged 60 Days or Younger. *JAMA*. 2016;316(8):846-57.
75. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. *BMC Medicine*. 2009;7(1):34.
76. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. *Am J Respir Crit Care Med*. 2015;191(3):309-15.
77. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. *The Lancet Respiratory Medicine*. 2016;4(4):259-71.
78. Scicluna BP. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. *Lancet Respir Med*. 2017;5.
79. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters. *Crit Care Med*. 2018;46(6):915-25.
80. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, Fleischmann-Struzek C, Pletz MW, Netea MG, et al. Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis\*. *Critical Care Medicine*. 2021;49(12):2042-57.
81. Cernada M, Pinilla-Gonzalez A, Kuligowski J, Morales JM, Lorente-Pozo S, Pineiro-Ramos JD, et al. Transcriptome profiles discriminate between Gram-positive and Gram-negative sepsis in preterm neonates. *Pediatr Res*. 2021.
82. Atreya MR, Wong HR. Precision medicine in pediatric sepsis. *Current opinion in pediatrics*. 2019;31(3):322-7.